肾动脉去交感神经术在治疗高血压中的研究进展

Abstract
Figure/Table
References (36)
Related Citation (15)

Download: PDF (713 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract

For a long time,the contradiction between the high incidence and the low control rate of hypertension has been a global problem.Many patients failto achieve or maintain the target blood-pressure that guideline recommended.To make up for the shortcomings of the traditional antihypertensive route,renal denervation has been widely studied in recent years as anew way to control blood pressure,in which catheter-directed techniques are used to ablate portions of the renal artery to reduce sympathetic activity.In the process of development of this technology,there are also twists and turns.At present,it has developed into three main procedures,including radiofrequency ablation,ultrasound ablation and ethanol ablation.It has increasingly been shown to be a safe and well-tolerated intravascular intervention that reliably lowers blood pressure and ultimately improves cardiovascular outcomes.At the same time,renal denervation may also play an important role in tachyarrhythmia and heart failure.This review aims to discuss the possible principles of this strategy,summarizethe classification and clinical evidence of this procedure,emphasize the advantages in lowering blood pressure throughout 24 hours and reducing themedication burden,point out the people that may benefit more from the procedure and highlight the possible directions for its future application.

Key words： Renal denervation Hypertension Radiofrequency Resistant hypertension

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2024/V31/I16/194

[1]	国家心血管病中心，中国医师协会，中国医师协会高血压专业委员会，等.中国高血压临床实践指南[J].中华心血管病杂志，2022，50（11）：1050-1095.
[2]	陈娜，樊瑛瑛，徐东香.高血压患者遵医嘱依从性的影响因素分析[J].中国医学创新，2022，19（23）：93-96.
[3]	Schmieder RE.Renal denervation in patients with chronic kidney disease：current evidence and future perspectives[J].Nephrol Dial Transplant，2022，38（5）：1089-1096.
[4]	Osborn JW，Tyshynsky R，Vulchanova L.Function of renal nerves in kidney physiology and pathophysiology[J].Annu Rev Physiol，2021，83：429-450.
[5]	Schmieder RE.Renal denervation：where do we stand and what is the relevance to the nephrologist[J].Nephrol Dial Transplant，2020，37（4）：638-644.
[6]	Grassi G，Seravalle G，Brambilla G，et al.Blood pressure responses to renal denervation precede and are independent of the sympathetic and baroreflex effects[J].Hypertension，2015，65（6）：1209-1216.
[7]	Krum H，Schlaich MP，Sobotka PA，et al.Percutaneous renaldenervation in patients with treatment-resistant hypertension：final 3-year report of the Symplicity HTN-1 study[J].Lancet，2014，383（9917）：622-629.
[8]	Esler MD，M，Sievert H，et al.Catheter-based renal denervation for treatment of patients with treatment-resistanthypertension：36 month results from the Symplicity HTN-2 randomized clinical trial[J].Eur Heart J，2014，35（26）：1752-1759.
[9]	Bakris GL，Townsend RR，Flack JM，et al.12-month blood pressure results of catheter-based renal artery denervationfor resistant hypertension：the Symplicity HTN-3 trial[J].J Am-Coll Cardiol，2015，65（13）：1314-1321.
[10]	Townsend RR，Mahfoud F，Kandzari DE，et al.Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications（SPYRAL HTN-OFF MED）：a randomised，sham-controlled，proof-ofconcept trial[J].Lancet，2017，390（10108）：2160-2170.
[11]	Mahfoud F，Kandzari DE，Kario K，et al.Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs（SPYRAL HTN-ON MED）：a randomised，sham-controlled trial[J].Lancet，2022，399（10333）：1401-1410.
[12]	Mauri L，Kario K，Basile J，et al.A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation：the RADIANCE-HTN and REQUIRE clinical study designs[J].Am Heart J，2018，195：115-129.
[13]	Azizi M，Daemen J，Lobo MD，et al.12-month results from the unblinded phase of the RADIANCE-HTN SOLO trial of ultrasound renal denervation[J].JACC Cardiovasc Interv，2020，13（24）：2922-2933.
[14]	Azizi M，Sanghvi K，Saxena M，et al.Ultrasound renal denervation for hypertension resistant to a triple medication pill（RADIANCE-HTN Trio）：a randomised，multicentre，singleblind，sham-controlled trial[J].Lancet，2021，397（10293）：2476-2486.
[15]	Kario K，Hoshide S，Mizuno H，et al.Nighttime blood pressure phenotype and cardiovascular prognosis：practitioner-based nationwide JAMP study[J].Circulation，2020，142（19）：1810-1820.
[16]	Azizi M，Saxena M，Wang Y，et al.Endovascular Ultrasound Renal Denervation to Treat Hypertension：The RADIANCE II Randomized Clinical Trial[J].JAMA，2023，329（8）：651-661.
[17]	Kario K，Yokoi Y，Okamura K，et al.Catheter-based ultrasound renal denervation in patients with resistant hypertension：the randomized，controlled REQUIRE trial[J].Hypertens Res，2022，45（2）：221-231.
[18]	Fengler K，Rommel KP，Blazek S，et al.A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension（RADIOSOUND-HTN）[J].Circulation，2019，139（5）：590-600.
[19]	Mahfoud F，Weber M，Schmieder RE，et al.Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension：design of two sham-controlled，randomized，blinded trials in the absence（TARGET BP OFF-MED）and presence（TARGET BP I）of antihypertensive medications[J].Am Heart J，2021，239：90-99.
[20]	Pathak A，Rudolph UM，Saxena M，et al.Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications[J].EuroIntervention，2023，19（7）：602-611.
[21]	Wang J，Sun N，Ge J，et al.Rationale and Design of Sympathetic Mapping/Ablation of Renal Nerves Trial（SMART）for the Treatment of Hypertension：a Prospective，Multicenter，Single-Blind，Randomized and Sham Procedure-Controlled Study[J].J Cardiovasc Transl Res，2023，16（2）：358-370.
[22]	Townsend RR，Walton A，Hettrick DA，et al.Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation[J].EuroIntervention，2020，16（1）：89-96.
[23]	Sanders MF，Reitsma JB，Morpey M，et al.Renal safety of catheter-based renal denervation：systematic review and meta-analysis[J].Nephrol Dial Transplant，2017，32（9）：1440-1447.
[24]	Mahfoud F，Mancia G，Schmieder R，et al.Renal denervation in high-risk patients with hypertension[J].J Am Coll Cardiol，2020，75（23）：2879-2888.
[25]	Rader F，Kirtane AJ，Wang Y，et al.Durability of blood pressure reduction after ultrasound renal denervation：three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial[J].EuroIntervention，2022，18（8）：e677-e685.
[26]	Kim BK，Kim HS，Park SJ，et al.Long-term outcomes after renal denervation in an Asianpopulation：results from the Global SYMPLICITY Registry in South Korea（GSR Korea）[J].Hypertens Res，2021，44（9）：1099-1104.
[27]	Fatani N，Dixon DL，Van Tassell BW，et al.Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension[J].J Am Coll Cardiol，2021，77（10）：1290-1299.
[28]	Fu G，Zhou Z，Jian B，et al.Systolic blood pressure time in target range and long-term outcomes in patients with ischemic cardiomyopathy[J].Am Heart J，2023，258：177-185.
[29]	KandzariDE，HickeyGL，PocockSJ，et al.Prioritisedendpoints for device-based hypertension trials：the win ratio methodology[J].EuroIntervention，2021，16（18）：e1496-e1502.
[30]	Steinberg JS，Shabanov V，Ponomarev D，et al.Effect of renal denervation and catheter ablationvscatheter ablation alone on atrial fibrillation recurrence among patients with paroxysmal atrial fibrillation and hypertension：the ERADICATE-AF randomized clinical trial[J].JAMA，2020，323（3）：248-255.
[31]	Kario K，Hoshide S，Narita K，et al.Cardiovascular prognosis indrug-resistanthypertensionstratifiedby24hourambulatory blood pressure：the JAMP study[J].Hypertension，2021，78（6）：1781-1790.
[32]	Kresoja KP，Rommel KP，Fengler K，et al.Renal sympathetic denervation in patients with heart failure with preserved ejection fraction[J].Circ Heart Fail，2021，14（3）：e007421.
[33]	Chia YC，Ahmad WAW，Fong AYY，et al.2022 Malaysian Working Group consensus statement on renal denervation for management of arterial hypertension[J].Hypertens Res，2022，45（7）：1111-1122.
[34]	Mancia G，Kreutz R，M，et al.2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension（ISH）and the European Renal Association（ERA）[J].J Hypertens，2023，41（12）：1874-2071.
[35]	Schmieder RE，Mahfoud F，Mancia G，et al.Members of the ESH Working Group on Device-Based Treatment of Hypertension.European Society of Hypertension position paper onrenal denervation 2021[J].J Hypertens，2021，39（9）：1733-1741.
[36]	Schmieder R，Burnier M，East C，et al.Renal Denervation：A Practical Guide for Health Professionals Managing Hypertension[J].Interv Cardiol，2023，18：e06.